No Detail Found!

Promising role of Metformin in reducing the viability of breast cancerous cells

Author(s)
Fatima Rizvi Department of Pharmacology, Dow International Medical College (DIMC),Karachi,Pakistan
Mahboob Alam Department of Pharmacology,BMSI, JPMC, Karachi,Pakistan
Farah Asad Department of Pharmacology,JMDC, Karachi,Pakistan
Abstract
To evaluate the anticancerous effects of different dilutions of metformin were evaluated for in vitro anticancerous effects, primarily breast cancer cells (MCF-7, MDA-MB-231). This prospective experimental study was conducted in Department of Pharmacology & Therapeutics BMSI in alliance with PCMD. The duration of study was from March 2016 to February 2017. For evaluating the anticancerous effects of different dilutions of Metformin (0.5µM -100µM) we used 4 different cancerous cells lines; MCF-7, HT-29, MDA-MB-231 and Hela. For assessment of anticancerous effects we used MTT assay by which assessed IC50, SI, % viability of all cells and Trypan blue exclusion assay for only MCF-7 cell line. The % viability of MCF-7 was significantly decreases (χ2 (2) = 26.48, p=<0.001) in dose dependent manner from 99.8±0.2 to 39.71±1.3. For MDA-MB-231% viability significantly reduced (χ2 (2) =26.48, p=<0.001) from 99.474± 0.298 to 51.55±4. However Metformin had statistically no significant dose dependent effects on % viability of MCF-10 (χ2 (2) = 11.709, p=0.069). Metformin significantly exhibited the anticancerous effects on breast cancerous cells by selectively target the cancerous cells without any effects on normal epithelial cells of breast.
Publication Details
Page(s) 543-549
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 2, Year: 2020

Request the full text from PASTIC

Keywords
Breast cancer, in vitro, viability assays, % viability, cancerous cell lines
0

Citations

0

Downloads

62

Views